Journal
CANCER
Volume 128, Issue 8, Pages 1568-1570Publisher
WILEY
DOI: 10.1002/cncr.34119
Keywords
acute myeloid leukemia; AML; blast percentage; classification; MDS
Categories
Funding
- Leukemia & Lymphoma Society Scholar in Clinical Research Award
- V Foundation Lloyd Family Clinical Scholar Award
- MD Anderson Cancer Center Leukemia Specialized Program of Research Excellence grant [P50 CA100632]
Ask authors/readers for more resources
When identifying the optimal therapy for a patient with a myeloid malignancy, focusing on the patient's characteristics and disease cytogenetic and mutational profile is more important than relying solely on the bone marrow blast percentage.
A fixed 20% blast percentage to discriminate myelodysplastic neoplasms from acute myeloid leukemia is arbitrary and overly simplistic. Key factors for identifying the optimal therapy for a patient with a myeloid malignancy should rely most on the patient's characteristics (particularly age and fitness/frailty) and disease cytogenetic and mutational profile, with less reliance on the bone marrow blast percentage.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
